Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0245)
Name
Fraxetin
Synonyms
Fraxetin; 574-84-5; 7,8-Dihydroxy-6-methoxycoumarin; 7,8-Dihydroxy-6-methoxy-2H-chromen-2-one; 7,8-dihydroxy-6-methoxychromen-2-one; 2H-1-Benzopyran-2-one, 7,8-dihydroxy-6-methoxy-; UNII-CD3GD44O3K; 7,8-Dihydroxy-6-methoxy-2-benzopyrone; CD3GD44O3K; 7,8-Dihydroxy-6-methoxy-chromen-2-one; CHEMBL54909; CHEBI:5169; EINECS 209-376-2; 7,8-Dihydroxy-6-methoxy-2H-1-benzopyran-2-one; Fraxetol; 8-hydroxyscopoletin; Spectrum_001507; SpecPlus_000477; FRAXETIN [MI]; Spectrum2_001639; Spectrum3_001842; Spectrum4_001686; Spectrum5_000332; Oprea1_735469; SCHEMBL43472; BSPBio_003224; Fraxetin, analytical standard; KBioGR_001952; KBioSS_001987; MLS002207123; DivK1c_006573; SPECTRUM1504069; SPBio_001737; MEGxp0_000506; ACon0_001071; ACon1_000442; KBio1_001517; KBio2_001987; KBio2_004555; KBio2_007123; KBio3_002724; DTXSID00205992; HAVWRBANWNTOJX-UHFFFAOYSA-N; 7,8-dihydroxy-6-methoxy coumarin; KUC106681N; HY-N0580; TNP00177; Coumarin, 7,8-dihydroxy-6-methoxy; BDBM50206215; CCG-38759; MFCD00006873; s9503; STL564671; Coumarin, 7,8-dihydroxy-6-methoxy-; AKOS000277991; 7,8-Dihydroxy-6-methoxycoumarin, 98%; NCGC00017270-01; NCGC00017270-02; NCGC00017270-03; NCGC00017270-04; NCGC00017270-05; NCGC00096046-01; NCGC00096046-02; NCGC00169075-01; NCGC00169075-02; AC-34572; AS-67313; SMR000112323; KSC-11-207-12; CS-0009115; FT-0632418; 7,8-Dihydroxy-6-methoxy-2H-chromen-2-one #; A14554; C09265; SR-05000002449; Q-100662; SR-05000002449-1; BRD-K76587808-001-03-8; Q15410973; InChI=1/C10H8O5/c1-14-6-4-5-2-3-7(11)15-10(5)9(13)8(6)12/h2-4,12-13H,1H

    Click to Show/Hide
Structure
Formula
C10H8O5
IUPAC Name
7,8-dihydroxy-6-methoxychromen-2-one
Canonical SMILES
COC1=C(C(=C2C(=C1)C=CC(=O)O2)O)O
InChI
InChI=1S/C10H8O5/c1-14-6-4-5-2-3-7(11)15-10(5)9(13)8(6)12/h2-4,12-13H,1H3
InChIKey
HAVWRBANWNTOJX-UHFFFAOYSA-N
PubChem CID
5273569
Full List of Ferroptosis Target Related to This Drug
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Acute myocardial infarction ICD-11: BA41
 Disease Info 
Responsed Regulator RAC-alpha serine/threonine-protein kinase (AKT1) Suppressor
 Regulator Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model CHO-S/H9C2 cells Normal Cricetulus griseus CVCL_A0TS
In Vivo Model
Male Wistar rats (200-250 g) were obtained from Slac Laboratory Animal Center (Shanghai, China) and kept in cages. The rats were anesthetized with 1% pentobarbital and then lied on its back. Thereafter, the left precordial area of the rats were shaved and disinfected, followed by trachea intubation for artificial ventilation. After the left thoracotomy, the heart was fully exposed and the left coronary artery (LAD) was ligated with a 6-0 prolene suture at 2-3 mm from its origin between the pulmonary artery conus and the left atrial appendage. After 30 min, the suture was gently removed to allow reperfusion for 2 h.

    Click to Show/Hide
Response regulation Fraxetin activated phosphorylation of AKT and Nrf2 nuclear accumulation in Myocardial infarction in vivoandin vitromodels. Moreover, Fra reduced the activity of serum LDH, the accumulation of iron and the MDA level, and increased GSH and glutathione peroxidase 4 (GPX4) in rats with MI.
References
Ref 1 Fraxetin attenuates ferroptosis in myocardial infarction via AKT/Nrf2/HO-1 signaling. Am J Transl Res. 2021 Sep 15;13(9):10315-10327. eCollection 2021.